MISSION The Clinical Ligand Assay Society mission is to establish and promote high standards in the science and application of ligand assay technology by encouraging research, educating practitioners, and fostering communication and cooperation among individuals in laboratories, in medicine, in academia and industry. In the last 30 years, ligand assay technology has exploded to encompass not only a variety of non-isotopic techniques besides the classical radioactive labeling one to quantitate immunoassays but also receptor assays and gene probe technology.
Specific goals of CLAS include: Maintenance of an organization concerned with the diagnostic, therapeutic and investigative use of ligand assays and related methods.
Improvement of the standards of ligand assay methods by promoting education, encouraging basic and clinical research and advancing the practice of ligand assay as applied to clinical laboratory diagnosis; biochemical research; diagnosis and therapy in veterinary sciences; applications in agricultural, environmental and industrial sciences.
Sponsoring of regional, national, and international meetings, scientific symposia, review courses, certification programs, workshops and publications to increase knowledge of ligand assay technology and its development and application.
Promotion of cooperation and mutual consultation among members working in laboratories, clinics, hospitals, educational institutions and industry.
| Contact Details: |
| 3139 S. Wayne Road |
| Wayne |
| Michigan |
| 48184 |
| United States of America |
| Tel: | (734) 722-6290 |
| Fax: | (734) 722-7006 |
| Email: | clas@clas.org |
| WWW: | www.clas.org/
|
|
Loading...
|
Press Releases on Clinical Ligand Assay Society:
|
 |
| James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 |
28th October, 2008 |
Xceed Molecular |
WELLESLEY, Mass., Oct. 28 /PRNewswire/ -- Xceed Molecular, a pioneer in
the development of cost-effective, easy-to-use gene-expression analysis
systems, announced that renowned breast cancer
|
| DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings |
3rd June, 2008 |
DIAGNOCURE INC. |
QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two of DiagnoCure Inc. (TSX:
CUR) products, the PCA3 marker for the detection of prostate cancer and GCC
for the staging of colorectal cancer, were
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 254 times since April 2007, the link to the organisation's website has been followed 38 times
Search for more companies in Wayne
Search for more companies in Michigan
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Clinical Ligand Assay Society
